Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
OGX-427 is an antisense oligonucleotide that targets HSBP1 (HSP27), which reduces Hsbp1 expression, potentially resulting in increased tumor cell apoptosis and improved sensitivity to other antitumor therapies (NCI Drug Dictionary).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Apatorsen||OGX-427|ISIS 306053||Apatorsen (OGX-427) is an antisense oligonucleotide that targets HSBP1 (HSP27), which reduces Hsbp1 expression, potentially resulting in increased tumor cell apoptosis and improved sensitivity to other anti-tumor therapies (PMID: 31420467).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT00959868||Phase I||Apatorsen||A Study for Treatment of Superficial Bladder Cancer Using OGX-427||Unknown status|
|NCT01681433||Phase II||Prednisone Abiraterone Apatorsen||OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone||Terminated|
|NCT01780545||Phase II||Apatorsen Docetaxel||Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer||Completed|